AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+48.83%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.88B
AUM Growth
+$3.88B
(+32%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
74.76%
Holding
127
New
34
Increased
29
Reduced
17
Closed
18
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$65.1M |
| 2 |
Arrowhead Research
ARWR
|
$57.4M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$29.5M |
| 4 |
Vera Therapeutics
VERA
|
$21.8M |
| 5 |
Solid Biosciences
SLDB
|
$21.2M |
Top Sells
| 1 |
CAVA Group
CAVA
|
$385M |
| 2 |
Cytokinetics
CYTK
|
$49.6M |
| 3 |
argenx
ARGX
|
$44.3M |
| 4 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$14.8M |
| 5 |
Natera
NTRA
|
$12.5M |
Sector Composition
| 1 | Healthcare | 50.84% |
| 2 | Consumer Discretionary | 48.42% |
| 3 | Technology | 0.53% |
| 4 | Real Estate | 0.1% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merus
MRUS
$4.98B
| $20.5M | 0.52% | +455,081 | New | +$20.5M |
|
27
NewAmsterdam Pharma
NAMS
$2.71B
| $18.9M | 0.48% | +800,000 | New | +$18.9M |
|
28
Tango Therapeutics
TNGX
$747M
| $17.4M | 0.44% | +2,194,841 | New | +$17.4M |
|
|
SLRN
29
DELISTED
ACELYRIN
SLRN
| $16.2M | 0.41% | 2,405,143 -630,745 | -21% | -$4.26M |
|
|
ALPN
30
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $16.1M | 0.41% | 405,784 +355,025 | +699% | +$14.1M |
|
|
CNTA
31
Centessa Pharmaceuticals
CNTA
$2.25B
| $16M | 0.41% | 1,412,500 +400,000 | +40% | +$4.52M |
|
32
Gossamer Bio
GOSS
$562M
| $15.7M | 0.4% | 13,308,968 +1,250,000 | +10% | +$1.48M |
|
33
Edgewise Therapeutics
EWTX
$1.51B
| $14.8M | 0.38% | +811,718 | New | +$14.8M |
|
|
SYRS
34
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $13.4M | 0.34% | 2,505,013 | – | – |
|
35
Sea Limited
SE
$110B
| $12.8M | 0.33% | 237,500 -134,500 | -36% | -$7.22M |
|
36
Lexeo Therapeutics
LXEO
$259M
| $12.6M | 0.32% | 801,716 +198,281 | +33% | +$3.11M |
|
37
Astria Therapeutics
ATXS
$349M
| $12.4M | 0.32% | +884,214 | New | +$12.4M |
|
38
Amicus Therapeutics
FOLD
$2.34B
| $11.9M | 0.3% | 1,011,776 -1,014,588 | -50% | -$12M |
|
39
Generation Bio
GBIO
$40.4M
| $11.5M | 0.29% | 2,830,591 +16,400 | +0.6% | +$66.7K |
|
40
Xenon Pharmaceuticals
XENE
$2.98B
| $10.9M | 0.28% | +253,387 | New | +$10.9M |
|
41
Celldex Therapeutics
CLDX
$1.47B
| $10.6M | 0.27% | +253,000 | New | +$10.6M |
|
42
Taysha Gene Therapies
TSHA
$797M
| $10.6M | 0.27% | 3,687,548 +24,444 | +0.7% | +$70.2K |
|
43
Denali Therapeutics
DNLI
$2.23B
| $10.3M | 0.26% | 502,899 -300,000 | -37% | -$6.16M |
|
44
Apogee Therapeutics
APGE
$2.17B
| $10.1M | 0.26% | +152,500 | New | +$10.1M |
|
45
Erasca
ERAS
$445M
| $9.73M | 0.25% | 4,721,194 | – | – |
|
|
AGEN
46
Agenus
AGEN
$133M
| $9.07M | 0.23% | 15,631,235 | – | – |
|
47
Seer Inc
SEER
$115M
| $9.03M | 0.23% | 4,750,000 | – | – |
|
48
Ultragenyx Pharmaceutical
RARE
$2.89B
| $8.31M | 0.21% | +177,932 | New | +$8.31M |
|
|
ELEV
49
DELISTED
Elevation Oncology
ELEV
| $7.76M | 0.2% | +1,513,015 | New | +$7.76M |
|
50
Ovid Therapeutics
OVID
$91M
| $7.63M | 0.19% | 2,500,000 | – | – |
|